US EditionOxford's Nipah virus vaccine wins EMA PRIME status in UK first
Summary by Open Access Government
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Oxford's Nipah virus vaccine wins EMA PRIME status in UK first
The University of Oxford has become the first UK academic institution to receive support from the European Medicines Agency’s (EMA) PRIority MEdicines (PRIME) scheme for its vaccine targeting the deadly Nipah virus Nipah virus is a fatal zoonotic disease, which the World Health Organization (WHO) has highlighted as a research priority due to its pandemic potential. There are currently no licensed vaccines or treatments for the Nipah virus. Oxfo…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
